Roy S. Herbst Explained

Roy S. Herbst (born January 16, 1963) is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

Education

After earning a BS and MS degree from Yale University, Herbst earned his Doctor of Medicine at Cornell University Medical College and his PhD in Molecular Cell Biology at The Rockefeller University in New York City. His clinical fellowships in Medicine and Hematology were completed at the Dana–Farber Cancer Institute and Brigham and Women's Hospital, respectively. Subsequently, he completed a MS degree in Clinical Translational Research at Harvard University in Cambridge, Massachusetts.[1] [2]

Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head & Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas.[3]

Starting in 2011, Herbst has been the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital.[4]

Career

Clinical research

Herbst's early career focused on the clinical development of novel targeted agents for the treatment of lung cancer, including the early phase development of therapies targeting the epidermal growth factor receptor and vascular endothelial growth factor receptor signaling pathways for the treatment of lung cancer.[5]

Herbst designed and led the national Biomarker-integrated Approaches of Targeted Therapy for Lung cancer Elimination (BATTLE) clinical trial.[6] He is the national principal investigator of clinical trial "Lung-MAP".[7] [8]

Herbst and his colleagues at Yale did early research on the presence of the immune checkpoint protein PD-L1 in tumors that may dictate response to the immunotherapy atezolizumab.[9] This work earned their team the Herbert Pardes Clinical Research Achievement Award from the Clinical Research Forum, its top award in the US for 2015.[10] [11]

Herbst leads a lung cancer-focused National Cancer Institute specialized programs of research excellence (SPORE) grant at Yale, investigating novel immune based therapies, new methods to combat treatment resistance and understanding mechanisms of brain metastasis.[12]

From 2015 to 2019, he served as Yale's representative Principal Investigator of the Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team.[13]

Professional service

Herbst holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research and the American College of Physicians.[14] [15] [16]

Select publications

Awards

External links

Notes and References

  1. Web site: Roy S. Herbst, MD, PhD, Receives 2016 Paul A. Bunn Jr. Scientific Award - The ASCO Post. 2021-03-10. ascopost.com.
  2. Web site: Dr. Roy S. Herbst - Medical Oncology - New Haven, CT. 2021-03-10. Castle Connolly. en.
  3. Web site: Dr. Roy S. Herbst – At the Limits. 2021-03-10.
  4. Web site: Roy S. Herbst, MD, PhD AACR Governance. 2021-03-10. American Association for Cancer Research (AACR). en.
  5. Pfeiffer. Naomi. 2003-11-10. Recurrent NSCLC: Novel Second-Line Treatment Options. Oncology Times. en-US. 25. 21. 37–38. 10.1097/01.COT.0000291057.16221.07. 75210600. 0276-2234.
  6. 2010-06-01. Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nature Reviews Drug Discovery. en. 9. 6. 423. 10.1038/nrd3199. 20514061 . 38114099. 1474-1784. free.
  7. Web site: Groundbreaking Collaborative Clinical Trial Launched Lung Cancer Master Protocol. 2021-03-10. www.lung-map.org. en.
  8. Web site: Leadership Lung Cancer Master Protocol. 2021-03-10. www.lung-map.org. en.
  9. Web site: Longer Survival Observed With Atezolizumab for High PD-L1 NSCLC. 2021-03-10. Targeted Oncology. October 2020 .
  10. Web site: Clinical Research Forum Awards, April 2015.
  11. Web site: Pembrolizumab confers sustained OS benefit in PD-L1-expressing non-small cell lung cancer. 2021-03-10. www.healio.com.
  12. Web site: About Us. www.yalecancercenter.org.
  13. Web site: The Researchers | SU2C-ACS Lung Cancer Dream Team. www.lungcancerdreamteam.org.
  14. https://ascopost.com/issues/june-3-2018-narratives-special-issue/2018-fellows-of-asco-recognized-during-annual-meeting/ "2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago"
  15. Web site: International Association for the Study of Lung Cancer announces president-elect, board members. 2021-03-10. www.healio.com.
  16. Web site: Scientific Advisory Board. 2021-03-10. Lung Cancer Research Foundation. en-US.
  17. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM . Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial . J Clin Oncol . 20 . 18 . 3815–25 . September 2002 . 12228201 . 10.1200/JCO.2002.03.038 .
  18. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH . Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 . J Clin Oncol . 22 . 5 . 785–94 . March 2004 . 14990633 . 10.1200/JCO.2004.07.215 . 2318/39988 . free .
  19. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A . Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer . J Clin Oncol . 23 . 11 . 2544–55 . April 2005 . 15753462 . 10.1200/JCO.2005.02.477 . free .
  20. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS . Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck . J Clin Oncol . 23 . 24 . 5578–87 . August 2005 . 16009949 . 10.1200/JCO.2005.07.120 . free .
  21. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J . Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial . Lancet . 377 . 9780 . 1846–54 . May 2011 . 21621716 . 4134127 . 10.1016/S0140-6736(11)60545-X .
  22. Khuri. Fadlo R.. Herbst. Roy S.. 2019. The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center. Cancer. 125. 10. 1593–1596. 10.1002/cncr.32045. 30825386 . 73513961. 1097-0142. free.
  23. Web site: IASLC Awards, 2016. 10 March 2021. International Association for the Study of Lung Cancer.
  24. Web site: GO2 Foundation for Lung Cancer presents awards. 2021-03-10. www.healio.com.
  25. Web site: 2020 AACR Distinguished Public Service Awards AACR News Releases. 2021-03-10. American Association for Cancer Research (AACR). en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Roy S. Herbst".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.